Purevax RC
Active substance
ATC code
Species
Cats
Indications
Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs.
Onset of immunity: 1 week after primary vaccination course.
Duration of immunity: 1 year after primary vaccination course and 3 years after the last re-vaccination.
Dose to be administered and administration route
Subcutaneous route.
Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation.
Visual appearance after reconstitution: clear slightly yellow suspension.
After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen) inject one dose of vaccine according to the following vaccination scheme:
Primary vaccination course:
- first injection: from 8 weeks of age,
- second injection: 3 to 4 weeks later.
Where high levels of maternal antibodies against rhinotracheitis or calicivirosis components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens, which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Revaccination:
- the first revaccination must be carried out one year after the primary vaccination course,
- subsequent revaccinations: at intervals of up to three years.
Adverse reactions
Cats:
Common (1 to 10 animals / 100 animals treated): | Apathy, anorexia, and hyperthermia1 Injection site reactions (pain, itching, oedema)2. |
Uncommon (1 to 10 animals / 1,000 animals treated): | Hypersensitivity reaction3 |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Emesis4 |
1 lasting usually for 1 or 2 days.
2 slight pain at palpation, itching or limited oedema disappearing within 1 or 2 weeks at most.
3 may require appropriate symptomatic treatment.4 mostly within 24 to 48 hours.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See section “Contact details” of the package leaflet.
PRICE | Only for registered vets. Create a free profile to access all features.. Login |
---|---|
Art. Nr. | 04491/5052 |
EAN | 4028691579359 |